Elicio Therapeutics, Inc. Operating Lease Right-of-Use Assets
Elicio Therapeutics, Inc. (ELTX) had Operating Lease Right-of-Use Assets of $4.29 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-13
- 2026-06-30: Operating Lease, Right-of-Use Asset $4.29M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $4.54M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $4.78M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $5.02M.
| Period end | Operating Lease, Right-of-Use Asset | Operating Lease, Right-of-Use Asset as first filed |
|---|---|---|
| 2026-06-30 | $4.29M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $4.54M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $4.78M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $5.02M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $5.25M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $5.48M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $5.71M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $5.93M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $6.14M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $6.35M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $6.56M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $6.77M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $6.95M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $126.00K 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $7.35M 10-K · filed 2024-03-29 | $152.00K 10-K · filed 2023-03-17 |
| 2022-09-30 | $3.38M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $3.59M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $3.79M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $3.99M 10-K · filed 2023-03-17 | |
| 2021-09-30 | $4.18M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $4.36M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $4.54M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $4.07M 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |